Latest news with #StephenBrady
Metro
28-07-2025
- Entertainment
- Metro
Scottish police drama with 'palpable tension' races up Netflix top 10 chart
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Netflix viewers are rushing to watch a 'suspenseful' Scottish crime drama that's drawn comparisons to Broadchurch. Initially airing on ITV in 2017, The Loch was created by Stephen Brady and follows DS Annie Redford (Breaking Bad's Laura Fraser), an officer with the Scottish Highland Police as she investigates the murder of piano teacher Niall Swift after he is found dead at the bottom of a cliff in the picturesque village of Lochnafoy, Loch Fyne, Inveraray. However, it quickly emerges that a serial killer is responsible after its discovered part of Swift's brain has been removed and a human heart belonging to another victim is found close by With a huge task ahead, Glasgow based major investigation detective DCI Lauren Quigley (Happy Valley's Siobhan Finneran) is then brought in to lead the enquiry. Last week the six-part series (which was titled Loch Ness in the US) was added to Netflix, with viewers quickly taking the chance to binge it. The Loch is now the second most-watched TV show in the UK on the platform. Wake up to find news on your TV shows in your inbox every morning with Metro's TV Newsletter. Sign up to our newsletter and then select your show in the link we'll send you so we can get TV news tailored to you. When the series first aired, critics said it was 'definitely worth a look'. 'This tartan-clad Broadchurch shows a lot of promise, not least in the way it plays on people's Loch Ness fascinations,' the Express wrote in its review. 'The peel-the-onion format here is familiar by now, but Stephen Brady's script and a group of fine performances keep it intriguing, nonetheless. A fine diversion for summer evenings,' The New York Times shared. Untamed Loch Ness Amy Bradley is Missing Critical: Between Life and Death Angi: Fake Life, True Crime The Sandman WWE Smack Down My Melody and Kuromi Squid Game The Jury 'You'll probably figure out the ending to Loch Ness well before the fog lifts, but my hunch is you're here mainly for the luscious scenery,' The Washington Post said. 'It does a good job of slowly building up a portrait of a troubled but brilliant man with little regard for authority but great regard for the law itself. Definitely worth a look,' The Post NZ added. Meanwhile user amwilson-50395 said the show 'feels fresh and has you second guessing at every clue uncovered'. 'The desire to uncover the truth is overwhelming. Suspenseful moments intertwined in a mix of both fast- and slow-moving plot points, if you are into British crime dramas, this needs to be added to your must watch list,' they wrote on IMDB. Others said it was 'compelling', 'gripping' and 'superb'. At the time of The Loch's premiere, its star Laura said the following when asked to describe it. 'It's all very dark and creepy but also has moments that are quite tongue-in-cheek. It reminds me a wee bit of the classic movie An American Werewolf in London. It has that that vibe and there's a lot of animal symbolism – wolves, crows, mutilated sheep and, of course, plenty of mentions of the Loch Ness monster.' More Trending When initially teasing details of the show, ITV shared: 'What secrets lie beneath the surface? In this stunningly set crime drama, some monsters are no myth. For Detective Annie Redford, the hunt is on to catch a killer. 'A murder in a small Scottish town sends the community into shock, and local detective Annie Redford is thrust into her first murder case.' The Loch also stars Don Gilet as psychological profiler Blake Albrighton, John Sessions as Annie's boss DCI Frank Smilie, Gray O'Brien as Alan Redford, Annie's husband, and William Ash as local tourist operator Leighton Thomas. View More » Loch Ness is streaming on Netflix. Got a story? If you've got a celebrity story, video or pictures get in touch with the entertainment team by emailing us celebtips@ calling 020 3615 2145 or by visiting our Submit Stuff page – we'd love to hear from you. MORE: Netflix quietly cancels 'gem of a series' with 100% on Rotten Tomatoes MORE: 7 films celebrating women in sport after the Lionesses win Euro 2025 MORE: 'I'll die on that hill': WWE star reveals moment she fought against bosses' plans
Yahoo
13-05-2025
- Business
- Yahoo
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP) Received FDA 'Study May Proceed' letter for Phase 2 trial of TPST-1495 for the treatment of FAP Granted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC) BRISBANE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2025 and provided a corporate update. 'The amezalpat program continues to produce data that reinforce its potential as a cancer therapy, most recently in a presentation at AACR showing that amezalpat reduced immunosuppression and activated the immune system to attack tumors. We were pleased to present these data that elucidate one part of the amezalpat mechanism of action and support the positive randomized Phase 2 data, including the benefit seen in patients with markers of immune resistance,' said Stephen Brady, president and chief executive officer of Tempest. 'We are actively engaged in exploring strategic alternatives to advance our promising clinical-stage programs and maximize stockholder value and, given the data, continue to have strong conviction in the potential of our oncology portfolio to drive meaningful impact for patients facing cancer.' ________________1 If approved by the U.S. Food and Drug Administration (FDA). Recent Highlights Amezalpat (TPST-1120) (clinical PPARα antagonist): Reported new data at the 2025 American Association for Cancer Research (AACR) Annual Meeting supporting the immune component of amezalpat's dual mechanism of action and reinforcing its potential as a novel cancer treatment. Granted both Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA) for amezalpat for the treatment of patients with HCC. TPST-1495 (clinical dual EP2/4 prostaglandin receptor antagonist): Granted Orphan Drug designation by the FDA to treat patients with FAP. Received a 'Study May Proceed' letter from the FDA for the Phase 2 trial for the treatment of FAP. This trial, run by CP-CTNet and financially supported by the NCI's Division of Cancer Prevention, underscores the urgent need for innovative cancer prevention strategies in high-risk patient populations. The Phase 2 study is expected to begin in 2025. Corporate: Announced (i) plans to explore a full range of strategic alternatives to advance the company's promising clinical-stage programs and maximize stockholder value and (ii) a reduction in force that was completed on April 30, 2025. Using cash on hand, the company repaid $3.5 million in full satisfaction of Loan and Security Agreement with Oxford Finance LLC in April 2025. Financial Results First Quarter 2025 Tempest ended the quarter with $21.5 million in cash and cash equivalents, compared to $30.3 million on December 31, 2024. The decrease was primarily due to cash used in operating activities, offset by proceeds of $1.5 million from the at-the-market offering program. Net loss and net loss per share for the quarter were $10.9 million and $3.16, respectively, compared to $7.9 million and $4.62, respectively, for the same period in 2024. Research and development expenses for the quarter were $7.6 million compared to $4.3 million for the same period in 2024. The $3.3 million increase was primarily due to an increase in costs incurred from engaging contract research and manufacturing organizations in preparation for our pivotal Phase 3 trial of amezalpat for the treatment of first-line HCC. General and administrative expenses for the quarter were $3.3 million compared to $3.6 million for the same period in 2024. The $0.3 million decrease was primarily due to a decrease in consulting services. About Tempest Therapeutics Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the 'Securities Act')) concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements contained in this press release include but are not limited to statements relating to Tempest Therapeutics' evaluation of strategic alternatives available to the company to maximize stockholder value and anticipated therapeutic benefit and regulatory development of Tempest Therapeutic' product candidates. Any forward-looking statements in this press release are based on Tempest Therapeutics' current expectations, estimates and projections about its industry as well as management's current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks relating to volatility and uncertainty in the capital markets for biotechnology companies; Tempest Therapeutics' ability to continue to operate as a going concern; availability of suitable third parties with which to conduct contemplated strategic transactions; whether we will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed on attractive terms or at all; unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the 'Risk Factors' section of the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 27, 2025, as well as in other filings the company may make with the SEC in the future. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics' views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics. TEMPEST THERAPEUTICS, INC. Consolidated Balance Sheets (in thousands) March 31,2025 December 31,2024 Assets Current assets Cash and cash equivalents $ 21,511 $ 30,268 Prepaid expenses and other current assets 922 1,206 Total current assets 22,433 31,474 Property and equipment, net 817 886 Operating lease right-of-use assets 8,376 8,643 Other noncurrent assets 538 485 Total assets $ 32,164 $ 41,488 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,187 $ 2,450 Accrued expenses 4,985 2,726 Current loan payable, net 4,190 6,354 Current operating lease liabilities 1,061 869 Accrued compensation 718 1,762 Interest payable 36 59 Total current liabilities 13,177 14,220 Operating lease liabilities 7,854 8,142 Total liabilities 21,031 22,362 Stockholders' equity Common stock(1) 4 3 Additional paid-in capital(1) 229,095 226,229 Accumulated deficit (217,966 ) (207,106 ) Total stockholders' equity 11,133 19,126 Total liabilities and stockholders' equity $ 32,164 $ 41,488 (1) Results have been adjusted to reflect the one-for-thirteen reverse stock split effected in April 2025. TEMPEST THERAPEUTICS, INC. Consolidated Statements of Operations (in thousands, except per share amounts) Three months ended Three months ended March 31, 2025 March 31, 2024 Expenses: Research and development $ 7,627 $ 4,340 General and administrative 3,309 3,634 Operating loss (10,936 ) (7,974 ) Other income (expense), net: Interest expense (161 ) (368 ) Interest and other income, net 237 438 Net loss $ (10,860 ) $ (7,904 ) Net loss per share(1) $ (3.16 ) $ (4.62 ) (1) Results have been adjusted to reflect the one-for-thirteen reverse stock split effected in April 2025. Investor Contacts: Sylvia WheelerWheelhouse Life Science Advisorsswheeler@ Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@
Yahoo
11-04-2025
- Business
- Yahoo
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Tempest Therapeutics is seeking a buyer or partner, saying Wednesday it has hired financial advisers to 'advance its promising clinical stage programs and maximize stockholder value,' as the California-based biotechnology company prepares a liver cancer drug for late-stage testing. Tempest didn't set a deadline for reaching a deal, and doesn't plan to disclose the nature of its talks or deal evaluation process until the company has 'determined that further disclosure is appropriate or necessary.' That cancer drug, called amezalpat, poses a 'rare opportunity for a partner,' according to CEO Stephen Brady, who pointed to supportive data as well as the drug being cleared for Phase 3 trials. Tempest ended 2024 with just over $30 million in cash and equivalents, which it cautioned was not enough to fully fund a Phase 3 trial. Brady said 'the capital markets have been unavailable' for the company to raise more money. The biotech sector has struggled through a funding drought as initial public offerings and secondary share sales alike have declined. Tempest had set out to find some additional funding, but with its market capitalization hovering around its cash holdings, a secondary offering wasn't a likely avenue of raising more cash. The company completed a one-for-13 share consolidation on Tuesday, just as world markets were battered by the imposition of global tariffs, many now watered down, by President Donald Trump. Tempest dodged some of the volatility of being a young biotech on the stock market, going public through a reverse merger with the University of Michigan spinout Millendo Therapeutics after the company had clinical setbacks. Millendo's corporate shell had formed through a different reverse merger with a company that worked in female infertility, called OvaScience, which also struggled in clinical studies. Tempest may have a promising asset in amezalpat. When combined with Roche's Tecentriq and Avastin in the first-line setting, amezalpat reduced the risk of death by 35% in people with hepatocellular carcinoma compared with the two Roche drugs by themselves. (The pairing of Tecentriq and Avastin are one of two recommended first-line treatments for hepatocellular carcinoma.) That Phase 2 trial also found people who received the amezalpat combination lived a median of 21 months, compared with 15 months for those getting only Tecentriq and Avastin. Based on that data, the Food and Drug Administration granted amezalpat fast-track designation as well as orphan drug status, both of which will ease some regulatory requirements. Tempest had also been cleared to begin its Phase 3 trial. Recommended Reading Athira exploring strategic alternatives after Alzheimer's failure Sign in to access your portfolio
